Literature DB >> 23913155

Drug-to-antibody ratio (DAR) and drug load distribution by LC-ESI-MS.

Louisette Basa1.   

Abstract

This chapter describes an LC-ESI-MS method for the DAR and drug load distribution analysis that is suitable for lysine-linked ADCs. The ADC sample is desalted using a reversed-phase LC column with an acetonitrile gradient prior to online MS analysis. The MS spectrum is processed (deconvoluted) and converted to a series of zero charge state masses that corresponds to the increasing number of drugs in the ADC. Integration of the mass peak area allows the calculation of the DAR and drug load distribution of ADCs.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23913155     DOI: 10.1007/978-1-62703-541-5_18

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  7 in total

1.  CD47-Targeted Near-Infrared Photoimmunotherapy for Human Bladder Cancer.

Authors:  Bernhard Kiss; Nynke S van den Berg; Robert Ertsey; Kelly McKenna; Kathleen E Mach; Chiyuan Amy Zhang; Jens-Peter Volkmer; Irving L Weissman; Eben L Rosenthal; Joseph C Liao
Journal:  Clin Cancer Res       Date:  2019-03-19       Impact factor: 12.531

Review 2.  Challenges and new frontiers in analytical characterization of antibody-drug conjugates.

Authors:  Anil Wagh; Hangtian Song; Ming Zeng; Li Tao; Tapan K Das
Journal:  MAbs       Date:  2018-01-05       Impact factor: 5.857

3.  Native mass spectrometry and ion mobility characterization of trastuzumab emtansine, a lysine-linked antibody drug conjugate.

Authors:  Julien Marcoux; Thierry Champion; Olivier Colas; Elsa Wagner-Rousset; Nathalie Corvaïa; Alain Van Dorsselaer; Alain Beck; Sarah Cianférani
Journal:  Protein Sci       Date:  2015-03-31       Impact factor: 6.725

4.  Real-Time Analysis on Drug-Antibody Ratio of Antibody-Drug Conjugates for Synthesis, Process Optimization, and Quality Control.

Authors:  Yubo Tang; Feng Tang; Yang Yang; Lei Zhao; Hu Zhou; Jinhua Dong; Wei Huang
Journal:  Sci Rep       Date:  2017-08-10       Impact factor: 4.379

5.  Anti-CDCP1 immuno-conjugates for detection and inhibition of ovarian cancer.

Authors:  Brittney S Harrington; Yaowu He; Tashbib Khan; Simon Puttick; Paul J Conroy; Thomas Kryza; Tahleesa Cuda; Kamil A Sokolowski; Brian Wc Tse; Katherine K Robbins; Buddhika J Arachchige; Samantha J Stehbens; Pamela M Pollock; Sarah Reed; S John Weroha; Paul Haluska; Carlos Salomon; Rohan Lourie; Lewis C Perrin; Ruby H P Law; James C Whisstock; John D Hooper
Journal:  Theranostics       Date:  2020-01-12       Impact factor: 11.556

Review 6.  Antibody-Drug Conjugates for Cancer Therapy: Chemistry to Clinical Implications.

Authors:  Nirnoy Dan; Saini Setua; Vivek K Kashyap; Sheema Khan; Meena Jaggi; Murali M Yallapu; Subhash C Chauhan
Journal:  Pharmaceuticals (Basel)       Date:  2018-04-09

7.  Effective targeting of intact and proteolysed CDCP1 for imaging and treatment of pancreatic ductal adenocarcinoma.

Authors:  Thomas Kryza; Tashbib Khan; Simon Puttick; Chao Li; Kamil A Sokolowski; Brian Wc Tse; Tahleesa Cuda; Nicholas Lyons; Madeline Gough; Julia Yin; Ashleigh Parkin; Elena I Deryugina; James P Quigley; Ruby H P Law; James C Whisstock; Andrew D Riddell; Andrew P Barbour; David K Wyld; Paul A Thomas; Stephen Rose; Cameron E Snell; Marina Pajic; Yaowu He; John D Hooper
Journal:  Theranostics       Date:  2020-03-04       Impact factor: 11.556

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.